Navigation Links
Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

se at the completion of combination therapy. Fifty of these patients received TELCYTA maintenance therapy and 50 did not receive maintenance therapy. Median progression-free survival for patients on TELCYTA maintenance therapy was 6.9 months, compared with 4.2 months for those who did not receive TELCYTA maintenance therapy (p< 0.0001, HR 0.36). Overall median survival for the TELCYTA-treated patients was 14.2 months compared with 8.4 months without TELCYTA maintenance therapy (p= 0.0003, HR 0.40).

The triplet combination was generally well-tolerated at all TELCYTA doses evaluated, with toxicities similar to those expected with each drug alone. There were no new, unexpected or cumulative toxicities. TELCYTA maintenance therapy was, as expected, well-tolerated, with Grade 1 or 2 toxicities observed in fewer than 5% of patients.

"Many approaches to maintenance therapy following first-line treatment for advanced non-small cell lung and ovarian cancer have been evaluated, with most adding little to efficacy while exposing patients to ongoing risks from toxic chemotherapy," said Gail L. Brown, M.D., senior vice president and chief medical officer. "The safety profile and clinical activity of TELCYTA, both in combination with carboplatin and paclitaxel and as monotherapy, suggest a potential role for this investigational agent as part of first-line combination treatment and as single agent maintenance therapy of non-small cell lung cancer. We will review these results with our expert advisors to discuss plans to expeditiously advance the TELCYTA program toward registration."

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung can
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer ... disc disease. Recently the FDA approved the ... disc, an innovative implant device developed by Spinal Kinetics, which ... in neck and or arm pain. Hospital for Special Surgery ... the only hospital in New York City ...
(Date:9/17/2014)... , Sept. 17, 2014  Members of the ... Interventional Associates announced today that the enterprise ... enhance its image sharing capabilities and provide immediate ... network failures. In addition, the Dicom Systems enterprise ... disparate PACS systems to more effectively deliver the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... 5, 2007 - First-in-human results for,IMC-A12, a monoclonal ... targeted to IGF-1R (insulin-like,growth factor type 1 receptor), ... Society of Clinical Oncology in Chicago.,The IGF-IR is ... cancers,and transmits signals that lead to tumor cell ...
... – This,year’s American Society of Clinical Oncology ... promising new data presented regarding,Merck KGaA’s targeted ... efficacy and,versatility of this agent in both ... (mCRC) and squamous cell,carcinoma of the head ...
Cached Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8
(Date:9/17/2014)... September 18, 2014 The global ablation ... of 9.6% from 2014 to 2019. Although mature markets ... hold larger shares in the ablation technologies market in ... the highest CAGR of 12.8% in the next five ... healthcare infrastructure, growing number of hospitals and surgical centers, ...
(Date:9/17/2014)... September 18, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has released its 2014 ... addition, the firm has launched a big sale for ... now available at deeply discounted rates, from 15 to ... the company insists on using comfortable to wear materials. ...
(Date:9/17/2014)... A ball gown is the most formal ... full-skirted gown reaching the floor, made of luxurious fabric, ... occasion gown manufacturer and retailer, has delightedly unveiled its ... gowns are offered at discounted rates. , Most versions ... gowns are typically worn with a stole (a formal ...
(Date:9/17/2014)... IntimateRider, an inventor of classy sexual enhancement ... it has entered into a dealership agreement with new ... reason for the deal is the fact that All ... its sales potential, representatives at the mobility products firm ... latest products on the market both nationally and internationally." ...
(Date:9/17/2014)... Dr. Shalev is a Texas native, and grew ... at the University of Texas, and graduated with a Bachelors ... real passion lay in dentistry, and she went on to ... Texas Health Science Center at Houston School of Dentistry. Dr. ... of The Greater Houston Dental Society, and the Texas Dental ...
Breaking Medicine News(10 mins):Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
... is a rapid latex agglutination ... of Helicobacter pylori total antibodies ... in the diagnosis of infection ... is intended for use to ...
... capillary electrophoresis system is designed to ... The CAPILLARYS 2 utilizes liquid flow ... diagnostic setting. Through continuous sample feed ... narrow capillary tubes functioning concurrently, a ...
Inquire...
These Iron Control Slides make an excellent addition to your laboratory. Packed ten (10) control slides per box. Use SDL's Snap n' Stain for Iron Staining Kit alongside to save time an money mixing r...
Medicine Products: